Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2020-01 Issue:1 Volume:5 Page:31-41
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Pose Elisa,Napoleone Laura,Amin Ahmed,Campion Daniela,Jimenez César,Piano Salvatore,Roux Olivier,Uschner Frank Erhard,de Wit Koos,Zaccherini Giacomo,Alessandria Carlo,Angeli Paolo,Bernardi Mauro,Beuers Ulrich,Caraceni Paolo,Durand François,Mookerjee Rajeshwar P,Trebicka Jonel,Vargas Victor,Andrade Raúl J,Carol Marta,Pich Judit,Ferrero Juan,Domenech Gema,Llopis Marta,Torres Ferran,Kamath Patrick S,Abraldes Juan G,Solà Elsa,Ginès Pere

Funder

Horizon 20/20

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Statins in cirrhosis—ready for prime time;Tsochatzis;Hepatology,2017

2. Statins: old drugs as new therapy for liver diseases?;Pose;J Hepatol,2019

3. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial;Abraldes;Gastroenterology,2009

4. Three months of simvastatin therapy vs placebo for severe portal hypertension in cirrhosis: a randomized controlled trial;Pollo-Flores;Dig Liver Dis,2015

5. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis;Abraldes;Gastroenterology,2016

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium;The Lancet Gastroenterology & Hepatology;2024-09

2. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

3. Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier;Hepatology International;2024-08-06

4. Pharmacologic Treatment of Portal Hypertension;Clinics in Liver Disease;2024-08

5. Optimizing the liver transplant candidate;npj Gut and Liver;2024-07-01